154 related articles for article (PubMed ID: 38521873)
1. Inconsistent Associations Between Risk Factor Profiles and Adjuvant Radiation Therapy (ART) Treatment in Patients with Cutaneous Squamous Cell Carcinoma and Utility of the 40-Gene Expression Profile to Refine ART Guidance.
Moody BR; Farberg AS; Somani AK; Taylor WA
Dermatol Ther (Heidelb); 2024 Apr; 14(4):861-873. PubMed ID: 38521873
[TBL] [Abstract][Full Text] [Related]
2. Association of a 40-Gene Expression Profile With Risk of Metastatic Disease Progression of Cutaneous Squamous Cell Carcinoma (cSCC) and Specification of Benefit of Adjuvant Radiation Therapy.
Arron ST; Cañueto J; Siegel J; Fitzgerald A; Prasai A; Koyfman SA; Yom SS
Int J Radiat Oncol Biol Phys; 2024 May; ():. PubMed ID: 38810706
[TBL] [Abstract][Full Text] [Related]
3. Integrating 40-GEP Testing to Improve Clinical Recommendations for Adjuvant Radiation for Cutaneous Squamous Cell Carcinoma: Multidisciplinary Consensus Guidelines.
Gopal R; Marquardt M; Singh G; Tolkachjov SN; Arron ST
J Clin Aesthet Dermatol; 2024 Mar; 17(3 Suppl 2):S3-S8. PubMed ID: 38495846
[TBL] [Abstract][Full Text] [Related]
4. Use of the 40-gene Expression Profile (40-GEP) Test in Medicare-eligible Patients Diagnosed with Cutaneous Squamous Cell Carcinoma (cSCC) to Guide Adjuvant Radiation Therapy (ART) Decisions Leads to a Significant Reduction in Healthcare Costs.
Somani AK; Ibrahim SF; Tassavor M; Yoo J; Farberg AS
J Clin Aesthet Dermatol; 2024 Jan; 17(1):41-44. PubMed ID: 38298751
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of the 40-Gene Expression Profile (40-GEP) Test to Improve Treatment Decisions in High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients: Case Series and Algorithm.
Singh G; Tolkachjov SN; Farberg AS
Clin Cosmet Investig Dermatol; 2023; 16():925-935. PubMed ID: 37051586
[TBL] [Abstract][Full Text] [Related]
6. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management.
Farberg AS; Hall MA; Douglas L; Covington KR; Kurley SJ; Cook RW; Dinehart SM
Curr Med Res Opin; 2020 Aug; 36(8):1301-1307. PubMed ID: 32351136
[No Abstract] [Full Text] [Related]
7. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
Wysong A; Somani AK; Ibrahim SF; Cañueto J; Fitzgerald AL; Siegel JJ; Prasai A; Goldberg MS; Farberg AS; Regula C; Bar A; Kasprzak J; Brodland DG; Koyfman SA; Arron ST
Dermatol Ther (Heidelb); 2024 Mar; 14(3):593-612. PubMed ID: 38424384
[TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test for Improved Patient Management Decisions and Disease-Related Outcomes when Combined with Current Clinicopathological Risk Factors for Cutaneous Squamous Cell Carcinoma (cSCC): Case Series.
Au JH; Hooper PB; Fitzgerald AL; Somani AK
Dermatol Ther (Heidelb); 2022 Feb; 12(2):591-597. PubMed ID: 34951694
[TBL] [Abstract][Full Text] [Related]
9. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.
Litchman GH; Fitzgerald AL; Kurley SJ; Cook RW; Rigel DS
Curr Med Res Opin; 2020 Aug; 36(8):1295-1300. PubMed ID: 32372702
[No Abstract] [Full Text] [Related]
10. Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma.
Arron ST; Wysong A; Hall MA; Bailey CN; Covington KR; Kurley SJ; Goldberg MS; Kasprzak JM; Somani AK; Ibrahim SF; Brodland DG; Cleaver NJ; Maher IA; Xia Y; Koyfman SA; Newman JG
Laryngoscope Investig Otolaryngol; 2022 Feb; 7(1):135-144. PubMed ID: 35155791
[TBL] [Abstract][Full Text] [Related]
11. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test.
Ibrahim SF; Kasprzak JM; Hall MA; Fitzgerald AL; Siegel JJ; Kurley SJ; Covington KR; Goldberg MS; Farberg AS; Trotter SC; Reed K; Brodland DG; Koyfman SA; Somani AK; Arron ST; Wysong A
Future Oncol; 2022 Mar; 18(7):833-847. PubMed ID: 34821148
[TBL] [Abstract][Full Text] [Related]
12. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study.
Dillon LD; McPhee M; Davidson RS; Quick AP; Martin B; Covington KR; Zolochevska O; Cook RW; Vetto JT; Jarell AD; Fleming MD
Curr Med Res Opin; 2022 Aug; 38(8):1267-1274. PubMed ID: 35081854
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Value and Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test in Cutaneous Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.
Masarwy R; Shilo S; Carmel Neiderman NN; Kampel L; Horowitz G; Muhanna N; Mansour J
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173922
[TBL] [Abstract][Full Text] [Related]
14. Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists.
Rebeca T; Giselle P; Litchman GH; Rigel DS
J Drugs Dermatol; 2019 Oct; 18(10):980-984. PubMed ID: 31584775
[TBL] [Abstract][Full Text] [Related]
15. Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
Hooper PB; Farberg AS; Fitzgerald AL; Siegel JJ; Rackley BB; Prasai A; Kurley SJ; Goldberg MS; Litchman GH
Cancer Invest; 2022 Nov; 40(10):911-922. PubMed ID: 36073945
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the utility of localized adjuvant radiation for node-negative primary cutaneous squamous cell carcinoma with clear histologic margins.
Ruiz ES; Koyfman SA; Que SKT; Kass J; Schmults CD
J Am Acad Dermatol; 2020 Feb; 82(2):420-429. PubMed ID: 31349042
[TBL] [Abstract][Full Text] [Related]
17. Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report.
Zakria D; Brownstone N; Berman B; Ceilley R; Cronin TA; Del Rosso JQ; Ferris LK; Goldenberg G; Siegel D
J Drugs Dermatol; 2024 Feb; 23(2):54-60. PubMed ID: 38306124
[TBL] [Abstract][Full Text] [Related]
18. Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report.
Zakria D; Brownstone N; Berman B; Ceilley R; Cronin TA; Del Rosso JQ; Ferris LK; Goldenberg G; Siegel D
J Drugs Dermatol; 2023 Dec; 22(12):7691. PubMed ID: 38051842
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma.
Wysong A; Newman JG; Covington KR; Kurley SJ; Ibrahim SF; Farberg AS; Bar A; Cleaver NJ; Somani AK; Panther D; Brodland DG; Zitelli J; Toyohara J; Maher IA; Xia Y; Bibee K; Griego R; Rigel DS; Meldi Plasseraud K; Estrada S; Sholl LM; Johnson C; Cook RW; Schmults CD; Arron ST
J Am Acad Dermatol; 2021 Feb; 84(2):361-369. PubMed ID: 32344066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
